{"id":"W2111879300","doi":"10.1634/theoncologist.2010-0081","title":"A Phase II Study of Pazopanib in Patients with Recurrent or Metastatic Invasive Breast Carcinoma: A Trial of the Princess Margaret Hospital Phase II Consortium","year":2010,"lang":"en","type":"article","venue":"The Oncologist","topic":"Angiogenesis and VEGF in Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":67,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre; Ottawa Hospital; University of Toronto; University Health Network; Sunnybrook Health Science Centre","funders":"National Cancer Institute; American Society of Clinical Oncology; BC Cancer Agency; AstraZeneca","keywords":"Pazopanib; Medicine; Metastatic breast cancer; Clinical endpoint; Internal medicine; Oncology; Neutropenia; Progressive disease; Breast cancer; Progression-free survival; Chemotherapy; Phases of clinical research; Cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Sunitinib","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001673995,0.001386158,0.001550245,0.0003054595,0.0003372536,0.0006886599,0.000965611,0.001426848,0.00339765],"category_scores_gemma":[0.0009471754,0.0004122197,0.0009603968,0.0003861683,0.0006769674,0.0004931681,0.0003146482,0.002620102,0.0007070178],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007891621,"about_ca_system_score_gemma":0.001154161,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008202858,"about_ca_topic_score_gemma":0.002146996,"domain_scores_codex":[0.9995806,0.0002398138,0.00001391896,0.00005408936,0.0000448402,0.00006677731],"domain_scores_gemma":[0.9993016,0.00009661556,0.0001606793,0.00004129224,0.0000487955,0.0003509648],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6798207,0.04849462,0.01143798,0.001895656,0.002172926,0.0006483013,0.0004368566,0.003621086,0.04196395,0.0006532071,0.01931963,0.1895351],"study_design_scores_gemma":[0.8409788,0.1363592,0.0140094,0.00004500902,0.0003346963,0.0005464363,0.00003360581,0.001177642,0.001859392,0.0001998243,0.004430917,0.0000250478],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9816457,0.006152869,0.0008509028,0.001607818,0.0001613984,0.00462294,0.001145184,0.0001290444,0.003684318],"genre_scores_gemma":[0.9716454,0.005323417,0.003371689,0.002787048,0.000332942,0.006998121,0.004245727,0.00004285532,0.005252812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00339765,"threshold_uncertainty_score":0.01136625,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02070113788703112,"score_gpt":0.3093775970581596,"score_spread":0.2886764591711286,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}